To clarify the tumor-binding activity and distribution of T-SA1 and T-SA2 in vivo, trastuzumab, T-SA1 and T-SA2 labeled with Cy5.5 were administered via tail vein injection to tumor-bearing BALB/c nude mice and the images were collected by bioluminescence imaging system at 2, 6, 12 and 24 h post injection. This evidence concerns the gene STAG1 and neoplasm.